TOEIC Link Biotechnology and Genomics Vocabulary: The 165-Word Cluster That Decides Discovery-and-Translation-Themed Items

Open any recent TOEIC Link Reading Part 6 booklet and a recurring document type keeps appearing — a vector-construct review memo circulated by a molecular-biology lead to a process-development manager, a sequencing-run quality-control advisory issued by a sequencing-platform operator to a bioinformatics analyst, an IND-enabling toxicology study readout prepared by a translational-research scientist for a regulatory-affairs liaison, a master-cell-bank release report circulated by a biologics-quality-control lead to a manufacturing-sciences director. The reason the biotechnology and genomics register has migrated onto the modern TOEIC Link from a life-sciences specialty into a recurring Part 6 cluster is structural — biotech-and-genomics work sits at the intersection of academic-translational discovery, pre-clinical and clinical development, biomanufacturing process science, and multi-jurisdiction regulatory submission, and the artifacts these operations produce fit the Part 6 short-passage format almost perfectly.

This article is the focused 165-word cluster that decides the biotechnology and genomics items on TOEIC Link Reading and Listening. It is organized by discovery-to-translation lifecycle stage — target identification, molecular construct work, sequencing and bioinformatics, pre-clinical pharmacology and toxicology, IND and regulatory submission, biomanufacturing process development, GMP manufacturing release, and clinical translation — because that is the structure the test uses to write the items and because biotech development follows the same arc.

Why the biotech-and-genomics register is structurally overweighted on the modern TOEIC Link

Three structural reasons keep this cluster disproportionately weighted on every recent test cycle.

Reason 1 — biotech artifacts are short, procedurally specific, and consequential. A vector-construct review memo, a sequencing quality advisory, an IND-enabling toxicology readout, or a master-cell-bank release report is a complete document that lands in 110 to 240 words. Part 6 reaches for these formats because they fit the question structure better than long-form research manuscripts.

Reason 2 — the biotech register is collocation-dense in operational communication. A single IND-enabling toxicology readout must do five things at once: report the no-observed-adverse-effect-level finding from the pivotal repeat-dose study, surface the histopathology findings against the safety-pharmacology core battery, propose the human-equivalent-dose calculation feeding the starting-dose rationale, request the toxicology-program-lead concurrence on the IND-package toxicology summary, and reserve the sponsor's right to stage additional bridging studies if the FDA pre-IND meeting flags gaps. Each of those moves has a fixed set of collocations the test rewards directly.

Reason 3 — the register has converged into a defined biotech lexicon. Biotech development has been standardized through the ICH harmonization framework (ICH Q5A-Q5E biologics quality, ICH S6 biotech-product safety, ICH E6 GCP, ICH Q8-Q11 product development), the FDA biologics CMC guidance, the EMA biosimilar pathway, the FDA Cellular and Gene Therapy guidance, and decades of biopharma platform convergence, so the terminology is unusually stable — vector, plasmid, expression construct, promoter, cell line, master cell bank, MCB, working cell bank, WCB, upstream, downstream, bioreactor, perfusion, fed-batch, chromatography, viral clearance, comparability, IND, investigational new drug, NOAEL, MTD, HED, GLP, GMP, CTD, common technical document. The test reaches for the converged vocabulary precisely because it is now standardized enough to grade fairly.

This is why our TOEIC Link vocabulary essentials guide now treats the biotechnology-and-genomics cluster as a foundational vertical alongside the pharmaceutical-and-clinical-trials cluster, the healthcare-and-medical cluster, and the academic-research-and-publishing cluster.

The 165-word cluster, organized by discovery-to-translation lifecycle stage

The cluster below is grouped by the discovery-to-translation lifecycle stage at which the passage is set. Memorize each group as a unit. The collocations are listed inline because the collocation is what the test rewards, not the bare lexical item.

Stage 1 — target identification and validation (≈18 words)

These are the framing words for the upstream phase where the discovery team translates a disease hypothesis into a validated molecular target.

Core nouns: disease hypothesis, target, target identification, target validation, druggability, modality, modality fit, target product profile, TPP, mechanism of action, MoA, pathway, node, biomarker, surrogate biomarker, pharmacodynamic biomarker, PD biomarker.

Core verbs: hypothesize, identify, validate, druggable, profile.

Common collocations: hypothesize the target against the disease mechanism, validate the target against the genetic-association evidence, profile the target against the druggability rubric, lock the target product profile against the modality decision, surface the pharmacodynamic biomarker against the mechanism of action.

Distractor pattern to watch: target (the molecular-target sense, the validated discovery entity that the program is engineered around) vs target (the everyday goal sense). The molecular-target sense is the biotech meaning.

Stage 2 — molecular construct work (≈22 words)

The construct-engineering stage produces the expression construct, the vector-map review memo, and the sequence-verification readout.

Core nouns: construct, expression construct, plasmid, vector, vector map, backbone, promoter, enhancer, terminator, signal peptide, codon optimization, restriction site, multiple cloning site, MCS, selection marker, antibiotic resistance, origin of replication, ori.

Core verbs: clone, ligate, transform, transfect, express, sequence-verify.

Common collocations: clone the gene of interest into the expression vector, ligate the insert into the backbone at the cloning site, transform the construct into the bacterial host, transfect the mammalian cell line with the optimized construct, express the protein from the validated cell pool, sequence-verify the construct against the reference design.

Stage 3 — sequencing and bioinformatics (≈20 words)

The sequencing stage produces the sequencing-run summary, the variant-call report, and the assembly-quality readout.

Core nouns: sequencing, next-generation sequencing, NGS, short-read, long-read, read depth, coverage, alignment, reference genome, variant, single-nucleotide variant, SNV, indel, insertion, deletion, copy number variant, CNV, structural variant, SV, assembly, contig.

Core verbs: sequence, align, call, assemble, annotate.

Common collocations: sequence the sample on the short-read platform, align the reads against the reference genome, call the variants against the quality threshold, assemble the contigs into the draft genome, annotate the variants against the clinical-significance database.

Stage 4 — pre-clinical pharmacology and toxicology (≈22 words)

The pre-clinical stage produces the in-vivo pharmacology study report, the GLP toxicology readout, and the safety-pharmacology core-battery summary.

Core nouns: pharmacology, pharmacokinetics, PK, pharmacodynamics, PD, exposure, half-life, clearance, volume of distribution, Vd, area under the curve, AUC, toxicology, tox, GLP, repeat-dose, single-dose, NOAEL, MTD, maximum tolerated dose, HED, human equivalent dose, safety pharmacology, core battery, genotoxicity.

Core verbs: dose, expose, observe, characterize, qualify.

Common collocations: dose the animals against the repeat-dose protocol, expose the cohort to the high-dose arm, observe the NOAEL against the histopathology endpoint, characterize the PK profile against the exposure window, qualify the safety pharmacology against the core-battery requirement.

Stage 5 — IND and regulatory submission (≈20 words)

The IND-package stage produces the IND-enabling package summary, the pre-IND meeting briefing document, and the regulatory-strategy memo.

Core nouns: IND, investigational new drug, pre-IND, pre-IND meeting, briefing document, CTD, common technical document, Module 1, Module 2, Module 3, Module 4, Module 5, clinical hold, partial clinical hold, IND safety report, expedited safety report.

Core verbs: file, submit, brief, respond, clear.

Common collocations: file the IND against the target submission date, submit the briefing document against the pre-IND meeting deadline, brief the agency against the modality-specific concerns, respond to the agency questions against the clinical hold criteria, clear the IND against the safe-to-proceed letter.

Stage 6 — biomanufacturing process development (≈22 words)

The process-development stage produces the upstream-process development readout, the downstream-process purification report, and the comparability-study memo.

Core nouns: process development, upstream, downstream, bioreactor, fed-batch, perfusion, seed train, inoculum, titer, viability, viable cell density, VCD, chromatography, affinity chromatography, ion exchange, hydrophobic interaction, viral clearance, filtration, ultrafiltration, diafiltration, UF/DF.

Core verbs: develop, scale, harvest, purify, characterize.

Common collocations: develop the upstream process against the titer target, scale the bioreactor against the working-volume specification, harvest the cells against the viable-cell-density trigger, purify the protein against the impurity-clearance target, characterize the product against the comparability protocol.

Stage 7 — GMP manufacturing release (≈21 words)

The GMP stage produces the master-cell-bank release report, the engineering-run summary, and the manufacturing-deviation investigation memo.

Core nouns: GMP, good manufacturing practice, master cell bank, MCB, working cell bank, WCB, engineering run, conformance lot, validation lot, release testing, certificate of analysis, CoA, deviation, out-of-specification, OOS, corrective and preventive action, CAPA, change control.

Core verbs: release, qualify, validate, investigate, disposition.

Common collocations: release the MCB against the safety-testing panel, qualify the engineering run against the comparability protocol, validate the manufacturing process against the conformance-lot criteria, investigate the deviation against the root-cause framework, disposition the lot against the release specification.

Stage 8 — clinical translation (≈20 words)

The translation stage produces the first-in-human protocol summary, the dose-escalation cohort review, and the proof-of-mechanism readout.

Core nouns: clinical translation, first-in-human, FIH, phase 1, dose escalation, dose-limiting toxicity, DLT, MAD, multiple ascending dose, SAD, single ascending dose, proof of mechanism, PoM, proof of concept, PoC, biomarker readout, target engagement, translational.

Core verbs: enroll, escalate, dose, engage, translate.

Common collocations: enroll the cohort against the FIH protocol, escalate the dose against the DLT criteria, dose the participant against the cohort-specific arm, engage the target against the PD biomarker readout, translate the pre-clinical model against the first-in-human exposure.

The eight collocations ETS recycles every test

If you have ninety minutes for vocabulary review the day before the test, drill these eight collocations. They appear on every recent test cycle and they decide a disproportionate share of Part 6 biotech-themed items.

1. file the IND against the target submission date
2. release the master cell bank against the safety-testing panel
3. align the reads against the reference genome
4. characterize the product against the comparability protocol
5. validate the target against the genetic-association evidence
6. qualify the safety pharmacology against the core-battery requirement
7. escalate the dose against the dose-limiting toxicity criteria
8. purify the protein against the impurity-clearance target

Three drills that move the cluster from passive to productive

The cluster above is the recognition target. The drills below are what move it from passive recognition to productive command.

Drill 1 — five-minute lifecycle-stage write-out. Set a five-minute timer. Without looking at the article, write the eight lifecycle stages in order and list five core nouns under each stage from memory. Compare against the article. The gap is your review queue for the next session.

Drill 2 — collocation reconstruction from a verb. Pick any verb from the cluster (file, release, align, characterize, validate, qualify, escalate, purify). Reconstruct the full collocation the article assigns to that verb without looking. Then reverse the drill — pick a noun and reconstruct the verb-side of the collocation.

Drill 3 — distractor sentence pairs. Write five sentence pairs in which the same lexical item is used in the biotech sense and the everyday sense (target, expression, vector, construct, validate). The Part 6 distractor pattern is to position the everyday sense as the wrong answer with the biotech sense as the correct one. Producing the contrast yourself stabilizes recognition under timed conditions.

The biotech-and-genomics cluster is one of the verticals that decides Part 6 outcomes on the modern TOEIC Link, and the 165 words organized by discovery-to-translation lifecycle stage are the structurally efficient route to productive command of the register the test rewards.